The program will feature presentations by:
- Mark Miller, M.D., Head of Infectious Diseases Division and Chair of Infection Prevention and Control Committee, SMBD Jewish Hospital in Montreal
- Pedro Lichtinger, President and CEO, Optimer
- Sherwood Gorbach, M.D., Chief Medical Officer, Optimer and Professor of Public Health & Medicine, Tufts University School of Medicine
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)
For additional information regarding this event, please contact Christina Donaghy, Corporate Communications Manager at Optimer Pharmaceuticals, at cdonaghy@optimerpharma.com.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA with the EMA (Europe) for fidaxomicin. Pruvel is a prodrug in the fluoroquinolone class of antibiotics that has completed two Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Contacts | |
Optimer Pharmaceuticals, Inc. | |
Christina Donaghy, Corporate Communications Manager | |
John D. Prunty, Chief Financial Officer & VP Finance | |
858-909-0736 | |
Canale Communications, Inc. | |
Jason I. Spark, Senior Vice President | |
619-849-6005 | |
SOURCE Optimer Pharmaceuticals, Inc.
